{"title": "PDF", "author": "PDF", "url": "https://infektiologie.co.at/wp-content/uploads/2021/10/2-Weinberger.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Immunogeniti\u00e4tund ImpfstoffauswahlBirgit WeinbergerUniversit\u00e4t InnsbruckInstitutf\u00fcrBiomedizinischeAlternsforschungBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021\u2022[ x] Ich gebe folgende potentielle Interessenskonflikte bekannt:\u2022[ ] Indirekte finanzielle Zuwendungen\u2022z.B. Forschungszusch\u00fcsse, Finanzierung von Studien, etc.\u2022[ x] Pers\u00f6nliche BeziehungenVortr\u00e4ge bei wissenschaftlichen Tagungen, Symposien auf Einladung von GSK, SanofiPasteur, Merck Vaccines, MSD\u2022im Zusammenhang mit dem Inhalt des Vortrags\u2022im Zeitraum der letzten drei Jahre\u2022bei/von pharmazeutischen  Unternehmen, Herstellern von Medizinprodukten, industriellen Interessenverb\u00e4ndenBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Ganzvirus-ImpfstoffInaktivierungmittelsFormaldehyd/\u00df-Propiolacton/ PsoralenSpaltvirus-ImpfstoffZerst\u00f6rungder Virusoberfl\u00e4chemitDetergentienSubunitAufreinigungspezifischerKomponenten(HA und NA)Subunit plus AdjuvansMF59\u00ae: \u00d6l-in-Wasser-Emulsion (Squalen, Tween80, Span25)High-Dose ImpfstoffSpaltvirus-Impfstoff, 4x h\u00f6hereAntigen-DosisVirosomenMembranvesikel(leereVirush\u00fclle); HA und NA auf der Oberfl\u00e4cheIntradermaleApplikationSpaltvirus-Impfstoff, wirdmittelsMikroinjektionssystemintradermal verabreichtAttenuierterLebendimpfstoffNasenspray; seit2014 f\u00fcrKinder und Jugendliche(2-18 J) zugelassenInfluenza-ImpfstoffeBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Impfungj\u00e4hrlichmitdemangepasstenImpfstoffUrspr\u00fcnglich3 Influenza-St\u00e4mme(trivalent, 2xA, 1xB)Eszirkulierenh\u00e4ufig2 verschiedeneB-St\u00e4mmegleichzeitigSeit2014/2015 gibtesquadrivalenteImpfstoffe, die 2 B-St\u00e4mmeenthaltenInfluenza: Impfempfehlung\n2017/20182018/20192019/20202020/20212021/2022A/H1N1Michigan/45/2015Michigan/45/2015Brisbane/02/2018Guangdong-Maonan/SWL1536/2019A/Victoria/2570/2019A/H3N2Hong Kong/4801/2014 Singapore/INFIMH-16-0019/2016Kansas/14/2017Hong Kong/2671/2019Cambodia/e0826360/2020BBrisbane/60/2008Colorado/06/2017Colorado/06/2017B/Washington/02/2019B/Washington/02/2019BPhuket/3073/2013Phuket/3073/2013Phuket/3073/2013Phuket/3073/2013Phuket/3073/2013Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021AktuelleImpfempfehlungen(2021)\nwww.sozialministerium.atEmpfehlungInfluenza Impfung(08.09.2021)Die Influenza-Impfung ist f\u00fcralle Erwachsenen empfohlen. Vorrangig empfohlen ist sie f\u00fcrPersonen ab dem vollendeten 60. Lebensjahr, chronisch Kranke, Personengruppen mit anderen Risikofaktoren sowie Personal im Gesundheitswesen und in der Altenpflege.Personen mit gesundheitlichen Risiken f\u00fcrschweren Verlauf sowie Kontaktpersonen/Haushaltskontakte von Personen mit gesundheitlichen Risiken f\u00fcrschweren Verlauf: \u2022Personen mit erh\u00f6hterGef\u00e4hrdunginfolge chronischer Erkrankungenwie zum Beispiel bei chronischen Lungen, Herz-, Kreislauferkrankungen, neurologischen Erkrankungen, Erkrankungen der Nieren, Stoffwechselkrankheiten (auch bei gut eingestelltem Diabetes mellitus) und Immundefekten\u2022Hospitalisierte Personen mit erh\u00f6hterGef\u00e4hrdungf\u00fcrInfluenza-Komplikationen \u2022Stark \u00fcbergewichtigePersonen (BMI\u226540) \u2022Bei HIV-Infektion oder anderen immunsuppressiven Erkrankungen\u2022Bei immunsuppressiven Therapien wie z.B. schwerer T-Zell-und B-Zell-Immunsuppressiva/Biologika-Therapie (z.B. Anti-CD20 AK): Impfung (2-)4 Wochen vor Therapiebeginn\u2022Schwangere und Frauen, die w\u00e4hrendder Influenzasaison schwanger werden wollen\u2022S\u00e4uglingeab dem vollendeten 6. Lebensmonat und Kleinkinder \u2022Kinder/Jugendliche ab dem vollendeten 6. Lebensmonat bis zu 18 Jahren unter Langzeit-Aspirin-Therapie (Verh\u00fctungeines ReyeSyndroms). Es ist zu beachten, dass in diesem Fall eine Lebendimpfung altersunabh\u00e4ngigkontraindiziert ist! \u2022Stillende und Personen im Umfeld von Neugeborenen \u2022Personen ab dem vollendeten 60. Lebensjahr und noch nachdr\u00fccklicherab dem vollendeten 65. Lebensjahr Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021AktuelleImpfempfehlungen(2021)\nwww.sozialministerium.atEmpfehlungInfluenza Impfung(08.09.2021)Die Influenza-Impfung ist f\u00fcralle Erwachsenen empfohlen. Vorrangig empfohlen ist sie f\u00fcrPersonen ab dem vollendeten 60. Lebensjahr, chronisch Kranke, Personengruppen mit anderen Risikofaktoren sowie Personal im Gesundheitswesen und in der Altenpflege.Infektionsrisiko auf Grund von Lebensumst\u00e4ndenoder Beruf: \u2022In Gemeinschaftseinrichtungen betreute Personen und Personal (z.B. Kinderbetreuungseinrichtungen, Schulen, soziale Einrichtungen/Sozialberufe, Alten-und Pflegeheime, etc.)\u2022Personal des Gesundheits-und Pflegebereichs \u2022Personen mit h\u00e4ufigemPublikumskontakt (wie z.B. Personal in Tourismus und Gastronomie, Friseur-und Kosmetikbetrieben, Handel, etc.) \u2022Alle Reisenden: Schutz w\u00e4hrendder Reise (z.B. am Flughafen, im Flugzeug) und am Reiseziel\u2013Impfung sp\u00e4testensca. 2 Wochen vor Reiseantritt (Influenzasaison tritt auf der S\u00fcdhalbkugeletwa um 1\u20442 Jahr verschoben von April\u2013September auf!). Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021AktuelleImpfempfehlungen(2021)\nwww.sozialministerium.atEmpfehlungInfluenza Impfung(08.09.2021)Kostendeckung:\u2022Kostenfrei im Kinderimpfprogramm (bis 15 Jahre)\u2022Kostenfrei in Alten-und Pflegeheimen\u2022Zusch\u00fcsseoder kostenfreie Impfungen gibt es bei einzelnen Arbeitgebern und Sozialversicherungs-tr\u00e4gernund in manchen Bundesl\u00e4ndernsowie bei ausgew\u00e4hltenImpfaktionen. Die Impfung f\u00fcrErwachsene wird jedoch nicht generell kostenfrei zur Verf\u00fcgunggestellt. Verf\u00fcgbare Impfstoffe:\u2022Kinder 2-18 Jahre: attenuierterLebendimpfstoff (Nasenspray)\u2022\u00e4ltere Erwachsene: Hochdosis (ab 60), adjvuantiert(ab 65)\u2022Standardimpfstoff: f\u00fcr alle Altersgruppen\u00e0zumerstenMal 2021/2022 alle quadrivalent verf\u00fcgbarBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Meta-Analyseaus31 Studien(1986-2002)\nH1N1H3N2B% seroconversion020406080100young elderly \nH1N1H3N2B% seroprotection020406080100young elderly \ndata from: Goodwin et al., Vaccine, 2006Influenza-ImpfstoffesindimAlter wenigerimmunogenBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Studien schwierig zu vergleichen, da-jedes Jahr ein anderer Impfstoff verwendet wird-die Pr\u00e4valenz von Influenza jedes Jahr anders ist-der Impfstoff unterschiedlich gut mit den tats\u00e4chlich zirkulierenden Viren \u00fcbereinstimmt-die Patientenkollektive unterschiedlich sind-die read-out Parameter unterschiedlich sind (Influenza-likeillness, Labordiagnose, Krankenhausaufenthalt wegen ILI\u2026)-kaum kontrollierte Placebo-Studien durchgef\u00fchrt werdenKonsensus besteht, dass-die Impfung bei j\u00fcngeren Personen besser wirkt als bei \u00e4lteren Menschen-die Impfung das Risiko von Krankenhausaufenthalten und Todesf\u00e4llen durch Influenza und Pneumonie verringertKlinischeWirksamkeitder Influenza-ImpfungBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021RandomisierteklinischeStudie:  HD-TIV vs SD-TIVH\u00f6hereAntigen-Dosis\u2022Trivalent 60\u00b5g HA pro Stamm statt 15\u00b5gzugelassen in USA (2010/2011)\u00e0h\u00f6here AK-Titer, h\u00f6here Serokonversion\u00e0besserer Schutz vor Influenza-Erkrankung\nn engl j med 371;7 nejm.org August 14, 2014641High-Dose vs. Standard-Dose Influenza VaccineTable/uni00202./uni0020Efficacy/uni0020of/uni0020High-Dose/uni0020Vaccine/uni0020Relative/uni0020to/uni0020Standard-Dose/uni0020Vaccine/uni0020against/uni0020Confirmed/uni0020Influenza/uni0020Caused/uni0020by/uni0020Any/uni0020Viral/uni0020Type/uni0020or/uni0020Subtype.*VariableLaboratory-Confirmed/uni0020Influenza\u2020Culture-Confirmed/uni0020InfluenzaIIV3-HD (N = 15,990) IIV3-SD (N = 15,993) Relative Efficacy  (95% CI)IIV3-HD (N = 15,990) IIV3-SD (N = 15,993) Relative Efficacy (95% CI)no. (%)%no. (%)% Protocol-defined influenza-like illness228 (1.4)301 (1.9)24.2 (9.7 to 36.5)\u2021206 (1.3)268 (1.7)23.1 (7.5 to 36.2)Influenza A190 (1.2)250 (1.6)24.0 (7.8 to 37.4)170 (1.1)222 (1.4)23.4 (6.0 to 37.6)A/H1N18 (<0.1)9 (0.1)11.1 (\u2212159.6 to 70.2)7 (<0.1)9 (0.1)22.2 (\u2212134.7 to 75.4)A/H3N2171 (1.1)223 (1.4)23.3 (6.0 to 37.5)156 (1.0)199 (1.2)21.6 (2.8 to 36.8)Influenza B38 (0.2)51 (0.3)25.5 (\u221215.7 to 52.4)36 (0.2)46 (0.3)21.7 (\u221223.8 to 50.8)Modified CDC-defined influenza-like illness96 (0.6)121 (0.8)20.6 (\u22124.6 to 39.9)84 (0.5)110 (0.7)23.6 (\u22122.4 to 43.2)Influenza A86 (0.5)104 (0.7)17.3 (\u221211.1 to 38.6)75 (0.5)94 (0.6)20.2 (\u22129.3 to 41.9)A/H1N13 (<0.1)2 (<0.1)\u221250.0 (\u22121696.0 to 82.8)2 (<0.1)2 (<0.1)0.0 (\u22121280.0 to 92.8)A/H3N277 (0.5)95 (0.6)18.9 (\u221210.7 to 40.8)69 (0.4)85 (0.5)18.8 (\u221212.9 to 41.8)Influenza B10 (0.1)17 (0.1)41.2 (\u221236.0 to 75.9)9 (0.1)16 (0.1)43.7 (\u221235.2 to 78.1)Respiratory illness316 (2.0)387 (2.4)18.3 (5.0 to 29.8)277 (1.7)339 (2.1)18.3 (3.9 to 30.5)Influenza A262 (1.6)313 (2.0)16.3 (1.0 to 29.2)227 (1.4)272 (1.7)16.5 (0.1 to 30.3)A/H1N114 (0.1)10 (0.1)\u221240.0 (\u2212252.4 to 42.2)13 (0.1)10 (0.1)\u221230.0 (\u2212231.3 to 47.33)A/H3N2231 (1.4)281 (1.8)17.8 (1.8 to 31.2)205 (1.3)246 (1.5)16.6 (\u22120.7 to 31.1)Influenza B54 (0.3)74 (0.5)27.0 (\u22125.1 to 49.6)50 (0.3)67 (0.4)25.4 (\u22129.3 to 49.3)*  CDC denotes Centers for Disease Control and Prevention.\u2020  Laboratory confirmation of influenza was accomplished by a positive result on culture of a nasopharyngeal swab, a positive polymerase-chain-reaction assay, or both.\u2021  The primary end point of the study was the occurrence, at least 14 days after vaccination, of laboratory-confirmed influenza caused by any influenza viral types or subtypes, in associa-tion with a protocol-defined influenza-like illness.\nThe New England Journal of Medicine Downloaded from nejm.org at KLINISCHE BIBLIOTHEK UNIV on May 29, 2020. For personal use only. No other uses without permission.  Copyright \u00a9 2014 Massachusetts Medical Society. All rights reserved. Falseyet al., J InfDis, 2009Chen et al., Vaccine, 2011DiazGranadoset al., NEJM, 2014Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Lee et al., Vaccine, 2021Systematic review and meta-analysis: HD-TIV vs. TIV (2009/2010 \u20132018/2019)H\u00f6hereAntigen-Dosis\nthat unmeasured confounders such as health-seeking behavior orselection bias could affect the \ufb01ndings of the observational studies.While early studies of HD-IIV3 saw limited use of the vaccineamong the total vaccinated cohort, leading to potential confound-ing by indication[40,49], recent studies may face an opposite prob-lem where widespread use of HD-IIV3 may lead to confoundingbias and statistical power issues if the number of SD-IIV recipientscontinues to decrease[26]. Nevertheless, the results from the addi-tionalmeta-analyses performed using only randomized or observa-tional studies were consistent with the overall pooled results,suggesting that we were able to observe a similar effect for HD-IIV3 irrespective of study design (see Table S3).Finally, it is also important to note that while sub-analyses wereperformed based on overall seasonal characteristics based on CDCviral surveillance data, most outcomes reported by the studiesidenti\ufb01ed by the systematic review were not laboratory-con\ufb01rmed, and that other in\ufb02uenza viral strains/subtypes can alsoco-circulate during the in\ufb02uenza season. Therefore, while thesesub-analyses are useful for policy and decision makers to examinehow HD-IIV3 performs in different types of in\ufb02uenza seasons, theydo not necessarily represent the strain-speci\ufb01c ef\ufb01cacy/effective-ness of HD-IIV3 against con\ufb01rmed in\ufb02uenza outcomes, or the rVEagainst speci\ufb01c matched/mismatched strains. Also, an importantcaveat to highlight is that sub-group analyses may lead to conclu-sions that are counterfactual to the overall results (i.e. lack of sta-tistical signi\ufb01cance in some of the sub-analyses by strain/match).In the model used in thesemeta-analyses, the summary effect, con-\ufb01dence intervals, and p-values were calculated based on theweighted average of each individual study effect. The weighting(per study; shown by the relative size of the data points inFig. 3) is a function of both within and between studies variance,where greater weight is assigned to studies with lower variance.This \u2018\u2018between studies\u201d variance implies that the summary effect,con\ufb01dence intervals, and consequently the p-values are dependenton both the number of studies (within the grouping/strata) in addi-tion to the variance exhibited by each of the selected studies forstrati\ufb01cation. Therefore, when stratifying a dataset such as the con-\ufb01rmed/probable ILI outcome (which is more variable than some ofthe other strata) for sub-analyses, it may result in the summaryeffect of the sub-analyses to have a wider con\ufb01dence intervaland a non-signi\ufb01cant p-value, even though the overall summaryeffect is statistically signi\ufb01cant. There also remain insuf\ufb01cient datafrom the identi\ufb01ed studies to perform additional subgroup analy-ses across multiple outcomes such as by age or by medical comor-bidities. Nevertheless, recently published and ongoing research isexpected to help address these remaining evidence gaps \u2013 forexample, Lu and colleagues recently published a study of the effectof age on the rVE of HD-IIV3 against in\ufb02uenza-related hospitalencounters among Medicare recipients[26]. Future research canfocus on performing these additional subgroup analyses shouldthe data become available.5. ConclusionsIn the ten years since its initial licensure in the US, HD-IIV3 hasseen both increasing uptake among older adults, and a growingbody of literature examining the impact of the vaccine in multiplesettings, in\ufb02uenza seasons and clinical outcomes \u2013 now includingover 34 million subjects and over 10 in\ufb02uenza seasons. Thisupdated systematic review andmeta-analysis con\ufb01rms our previ-ous \ufb01ndings and shows that irrespective of circulating strain andTable 3Pooled relative vaccine ef\ufb01cacy/effectiveness of HD-IIV3 vs. SD-IIV against in\ufb02uenza-related outcomes.Outcome All Seasons Predominant Circulating StrainaAntigenic Similarity with PredominantCirculating StrainbA/H3N2-predominantSeasonsA/H1N1-predominantSeasonsMatched Seasons Mismatched Seasonsn rVEc(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-valueIn\ufb02uenza-likeIllnessd715.9%(4.1\u201326.3%)0.01 418.3%(0.8\u201332.7%)0.041 3 10.7%(-6.1\u201324.8%)0.199 3 27.0%(-6.8\u201350.1%)0.105 4 14.3%(-3.4\u201329.0%)0.107In\ufb02uenza Hospitalizatione1011.7%(7.0 \u2013 16.1%)<0.001 712.1%(6.3 \u2013 17.6%)<0.001 39.6%(2.1\u201318.9%)<0.001 310.9%(2.1\u201318.9%)0.016 712.1%(6.3 \u2013 17.6%)<0.001Pneumonia Hospitalizationf427.3%(15.3\u201337.6%)<0.001 239.9%(19.3\u201355.3%)<0.001 222.0%(6.7\u201334.8%)<0.001 328.9%(10.1\u201343.8%)0.004 1 \u2013 \u2013Pneumonia/In\ufb02uenza Hospitalizationg713.4%(7.3\u201319.2%)<0.001 512.4%(5.7\u201318.7%)<0.001 219.6%(3.0\u201333.4%)0.023 513.5%(5.0\u201321.3%)0.002 213.3%(4.1\u201321.6%)0.005Cardiorespiratory Hospitalization717.9%(15.0\u201320.8%)<0.001 617.7%(14.5\u201320.8%)<0.001 1 \u2013 \u2013 417.4%(13.5\u201321.1%)<0.001 318.6%(14.1\u201322.9%)<0.001All-cause Hospitalization118.4%(5.7\u201311.0%)<0.001 88.3%(4.5\u201312.0%)<0.001 38.9%(5.4\u201312.2%)<0.001 76.4%(4.1\u20138.6%)<0.001 412.6%(7.8\u201317.2%)<0.001Post-in\ufb02uenza Mortality2 22.2%(-18.2\u201348.8%)0.240 1 \u2013 \u2013 1 \u2013 \u2013 1 \u2013 \u2013 1 \u2013 \u2013Pneumonia/In\ufb02uenza Mortality339.9%(18.6\u201355.6%)<0.001 243.2%(18.1 \u2013 60.6%)0.002 1 \u2013 \u2013 1 \u2013 \u2013 243.2%(18.1 \u2013 60.6%)0.002Cardiorespiratory Mortality327.7%(13.2\u201332.0%)<0.001 227.3%(20.3 \u2013 33.6%)<0.001 1 \u2013 \u2013 1 \u2013 \u2013 227.3%(20.3 \u2013 33.6%)<0.001All-cause Mortality5 2.5%(-5.1\u20139.5%)0.514 4 4.6%(-12.6\u201319.3%)0.575 1 \u2013 \u2013 3 0.7%(-4.3\u20135.6%)0.768 217.3%(0.2\u201331.5%)0.048aDetermined using national CDC viral surveillance data of circulating strains in adults 65 years of age and older.bBased on CDC data on viral antigenic characterization comparing reference vaccine strains to circulating viruses; mismatched seasons includes seasons of antigenicmismatch (2009\u201310, 2014\u201315, 2018\u201319) as well as seasons where egg-adapted vaccine strains may have affected vaccine effectiveness (2012\u201313, 2016\u201317, 2017\u201318). cA random-effects model with DerSimonian-Laird estimators was used to calculate the pooled OR across multiple studies and in\ufb02uenza seasons.dProbable/laboratory con\ufb01rmed in\ufb02uenza-like illness.eICD-9-CM 487 coded hospitalizations.fICD-9-CM 480\u2013486 coded hospitalizations.gICD-9-CM 480\u2013488 coded hospitalizations.J.K.H. Lee et al.Vaccine xxx (xxxx) xxx\n10Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Lee et al., Vaccine, 2021Systematic review and meta-analysis: HD-TIV vs. TIV (2009/2010 \u20132018/2019)H\u00f6hereAntigen-Dosis\nthat unmeasured confounders such as health-seeking behavior orselection bias could affect the \ufb01ndings of the observational studies.While early studies of HD-IIV3 saw limited use of the vaccineamong the total vaccinated cohort, leading to potential confound-ing by indication[40,49], recent studies may face an opposite prob-lem where widespread use of HD-IIV3 may lead to confoundingbias and statistical power issues if the number of SD-IIV recipientscontinues to decrease[26]. Nevertheless, the results from the addi-tionalmeta-analyses performed using only randomized or observa-tional studies were consistent with the overall pooled results,suggesting that we were able to observe a similar effect for HD-IIV3 irrespective of study design (see Table S3).Finally, it is also important to note that while sub-analyses wereperformed based on overall seasonal characteristics based on CDCviral surveillance data, most outcomes reported by the studiesidenti\ufb01ed by the systematic review were not laboratory-con\ufb01rmed, and that other in\ufb02uenza viral strains/subtypes can alsoco-circulate during the in\ufb02uenza season. Therefore, while thesesub-analyses are useful for policy and decision makers to examinehow HD-IIV3 performs in different types of in\ufb02uenza seasons, theydo not necessarily represent the strain-speci\ufb01c ef\ufb01cacy/effective-ness of HD-IIV3 against con\ufb01rmed in\ufb02uenza outcomes, or the rVEagainst speci\ufb01c matched/mismatched strains. Also, an importantcaveat to highlight is that sub-group analyses may lead to conclu-sions that are counterfactual to the overall results (i.e. lack of sta-tistical signi\ufb01cance in some of the sub-analyses by strain/match).In the model used in thesemeta-analyses, the summary effect, con-\ufb01dence intervals, and p-values were calculated based on theweighted average of each individual study effect. The weighting(per study; shown by the relative size of the data points inFig. 3) is a function of both within and between studies variance,where greater weight is assigned to studies with lower variance.This \u2018\u2018between studies\u201d variance implies that the summary effect,con\ufb01dence intervals, and consequently the p-values are dependenton both the number of studies (within the grouping/strata) in addi-tion to the variance exhibited by each of the selected studies forstrati\ufb01cation. Therefore, when stratifying a dataset such as the con-\ufb01rmed/probable ILI outcome (which is more variable than some ofthe other strata) for sub-analyses, it may result in the summaryeffect of the sub-analyses to have a wider con\ufb01dence intervaland a non-signi\ufb01cant p-value, even though the overall summaryeffect is statistically signi\ufb01cant. There also remain insuf\ufb01cient datafrom the identi\ufb01ed studies to perform additional subgroup analy-ses across multiple outcomes such as by age or by medical comor-bidities. Nevertheless, recently published and ongoing research isexpected to help address these remaining evidence gaps \u2013 forexample, Lu and colleagues recently published a study of the effectof age on the rVE of HD-IIV3 against in\ufb02uenza-related hospitalencounters among Medicare recipients[26]. Future research canfocus on performing these additional subgroup analyses shouldthe data become available.5. ConclusionsIn the ten years since its initial licensure in the US, HD-IIV3 hasseen both increasing uptake among older adults, and a growingbody of literature examining the impact of the vaccine in multiplesettings, in\ufb02uenza seasons and clinical outcomes \u2013 now includingover 34 million subjects and over 10 in\ufb02uenza seasons. Thisupdated systematic review andmeta-analysis con\ufb01rms our previ-ous \ufb01ndings and shows that irrespective of circulating strain andTable 3Pooled relative vaccine ef\ufb01cacy/effectiveness of HD-IIV3 vs. SD-IIV against in\ufb02uenza-related outcomes.Outcome All Seasons Predominant Circulating StrainaAntigenic Similarity with PredominantCirculating StrainbA/H3N2-predominantSeasonsA/H1N1-predominantSeasonsMatched Seasons Mismatched Seasonsn rVEc(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-valueIn\ufb02uenza-likeIllnessd715.9%(4.1\u201326.3%)0.01 418.3%(0.8\u201332.7%)0.041 3 10.7%(-6.1\u201324.8%)0.199 3 27.0%(-6.8\u201350.1%)0.105 4 14.3%(-3.4\u201329.0%)0.107In\ufb02uenza Hospitalizatione1011.7%(7.0 \u2013 16.1%)<0.001 712.1%(6.3 \u2013 17.6%)<0.001 39.6%(2.1\u201318.9%)<0.001 310.9%(2.1\u201318.9%)0.016 712.1%(6.3 \u2013 17.6%)<0.001Pneumonia Hospitalizationf427.3%(15.3\u201337.6%)<0.001 239.9%(19.3\u201355.3%)<0.001 222.0%(6.7\u201334.8%)<0.001 328.9%(10.1\u201343.8%)0.004 1 \u2013 \u2013Pneumonia/In\ufb02uenza Hospitalizationg713.4%(7.3\u201319.2%)<0.001 512.4%(5.7\u201318.7%)<0.001 219.6%(3.0\u201333.4%)0.023 513.5%(5.0\u201321.3%)0.002 213.3%(4.1\u201321.6%)0.005Cardiorespiratory Hospitalization717.9%(15.0\u201320.8%)<0.001 617.7%(14.5\u201320.8%)<0.001 1 \u2013 \u2013 417.4%(13.5\u201321.1%)<0.001 318.6%(14.1\u201322.9%)<0.001All-cause Hospitalization118.4%(5.7\u201311.0%)<0.001 88.3%(4.5\u201312.0%)<0.001 38.9%(5.4\u201312.2%)<0.001 76.4%(4.1\u20138.6%)<0.001 412.6%(7.8\u201317.2%)<0.001Post-in\ufb02uenza Mortality2 22.2%(-18.2\u201348.8%)0.240 1 \u2013 \u2013 1 \u2013 \u2013 1 \u2013 \u2013 1 \u2013 \u2013Pneumonia/In\ufb02uenza Mortality339.9%(18.6\u201355.6%)<0.001 243.2%(18.1 \u2013 60.6%)0.002 1 \u2013 \u2013 1 \u2013 \u2013 243.2%(18.1 \u2013 60.6%)0.002Cardiorespiratory Mortality327.7%(13.2\u201332.0%)<0.001 227.3%(20.3 \u2013 33.6%)<0.001 1 \u2013 \u2013 1 \u2013 \u2013 227.3%(20.3 \u2013 33.6%)<0.001All-cause Mortality5 2.5%(-5.1\u20139.5%)0.514 4 4.6%(-12.6\u201319.3%)0.575 1 \u2013 \u2013 3 0.7%(-4.3\u20135.6%)0.768 217.3%(0.2\u201331.5%)0.048aDetermined using national CDC viral surveillance data of circulating strains in adults 65 years of age and older.bBased on CDC data on viral antigenic characterization comparing reference vaccine strains to circulating viruses; mismatched seasons includes seasons of antigenicmismatch (2009\u201310, 2014\u201315, 2018\u201319) as well as seasons where egg-adapted vaccine strains may have affected vaccine effectiveness (2012\u201313, 2016\u201317, 2017\u201318). cA random-effects model with DerSimonian-Laird estimators was used to calculate the pooled OR across multiple studies and in\ufb02uenza seasons.dProbable/laboratory con\ufb01rmed in\ufb02uenza-like illness.eICD-9-CM 487 coded hospitalizations.fICD-9-CM 480\u2013486 coded hospitalizations.gICD-9-CM 480\u2013488 coded hospitalizations.J.K.H. Lee et al.Vaccine xxx (xxxx) xxx\n10Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Lee et al., Vaccine, 2021Systematic review and meta-analysis: HD-TIV vs. TIV (2009/2010 \u20132018/2019)H\u00f6hereAntigen-Dosis\nthat unmeasured confounders such as health-seeking behavior orselection bias could affect the \ufb01ndings of the observational studies.While early studies of HD-IIV3 saw limited use of the vaccineamong the total vaccinated cohort, leading to potential confound-ing by indication[40,49], recent studies may face an opposite prob-lem where widespread use of HD-IIV3 may lead to confoundingbias and statistical power issues if the number of SD-IIV recipientscontinues to decrease[26]. Nevertheless, the results from the addi-tionalmeta-analyses performed using only randomized or observa-tional studies were consistent with the overall pooled results,suggesting that we were able to observe a similar effect for HD-IIV3 irrespective of study design (see Table S3).Finally, it is also important to note that while sub-analyses wereperformed based on overall seasonal characteristics based on CDCviral surveillance data, most outcomes reported by the studiesidenti\ufb01ed by the systematic review were not laboratory-con\ufb01rmed, and that other in\ufb02uenza viral strains/subtypes can alsoco-circulate during the in\ufb02uenza season. Therefore, while thesesub-analyses are useful for policy and decision makers to examinehow HD-IIV3 performs in different types of in\ufb02uenza seasons, theydo not necessarily represent the strain-speci\ufb01c ef\ufb01cacy/effective-ness of HD-IIV3 against con\ufb01rmed in\ufb02uenza outcomes, or the rVEagainst speci\ufb01c matched/mismatched strains. Also, an importantcaveat to highlight is that sub-group analyses may lead to conclu-sions that are counterfactual to the overall results (i.e. lack of sta-tistical signi\ufb01cance in some of the sub-analyses by strain/match).In the model used in thesemeta-analyses, the summary effect, con-\ufb01dence intervals, and p-values were calculated based on theweighted average of each individual study effect. The weighting(per study; shown by the relative size of the data points inFig. 3) is a function of both within and between studies variance,where greater weight is assigned to studies with lower variance.This \u2018\u2018between studies\u201d variance implies that the summary effect,con\ufb01dence intervals, and consequently the p-values are dependenton both the number of studies (within the grouping/strata) in addi-tion to the variance exhibited by each of the selected studies forstrati\ufb01cation. Therefore, when stratifying a dataset such as the con-\ufb01rmed/probable ILI outcome (which is more variable than some ofthe other strata) for sub-analyses, it may result in the summaryeffect of the sub-analyses to have a wider con\ufb01dence intervaland a non-signi\ufb01cant p-value, even though the overall summaryeffect is statistically signi\ufb01cant. There also remain insuf\ufb01cient datafrom the identi\ufb01ed studies to perform additional subgroup analy-ses across multiple outcomes such as by age or by medical comor-bidities. Nevertheless, recently published and ongoing research isexpected to help address these remaining evidence gaps \u2013 forexample, Lu and colleagues recently published a study of the effectof age on the rVE of HD-IIV3 against in\ufb02uenza-related hospitalencounters among Medicare recipients[26]. Future research canfocus on performing these additional subgroup analyses shouldthe data become available.5. ConclusionsIn the ten years since its initial licensure in the US, HD-IIV3 hasseen both increasing uptake among older adults, and a growingbody of literature examining the impact of the vaccine in multiplesettings, in\ufb02uenza seasons and clinical outcomes \u2013 now includingover 34 million subjects and over 10 in\ufb02uenza seasons. Thisupdated systematic review andmeta-analysis con\ufb01rms our previ-ous \ufb01ndings and shows that irrespective of circulating strain andTable 3Pooled relative vaccine ef\ufb01cacy/effectiveness of HD-IIV3 vs. SD-IIV against in\ufb02uenza-related outcomes.Outcome All Seasons Predominant Circulating StrainaAntigenic Similarity with PredominantCirculating StrainbA/H3N2-predominantSeasonsA/H1N1-predominantSeasonsMatched Seasons Mismatched Seasonsn rVEc(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-value n rVE(95%CI)p-valueIn\ufb02uenza-likeIllnessd715.9%(4.1\u201326.3%)0.01 418.3%(0.8\u201332.7%)0.041 3 10.7%(-6.1\u201324.8%)0.199 3 27.0%(-6.8\u201350.1%)0.105 4 14.3%(-3.4\u201329.0%)0.107In\ufb02uenza Hospitalizatione1011.7%(7.0 \u2013 16.1%)<0.001 712.1%(6.3 \u2013 17.6%)<0.001 39.6%(2.1\u201318.9%)<0.001 310.9%(2.1\u201318.9%)0.016 712.1%(6.3 \u2013 17.6%)<0.001Pneumonia Hospitalizationf427.3%(15.3\u201337.6%)<0.001 239.9%(19.3\u201355.3%)<0.001 222.0%(6.7\u201334.8%)<0.001 328.9%(10.1\u201343.8%)0.004 1 \u2013 \u2013Pneumonia/In\ufb02uenza Hospitalizationg713.4%(7.3\u201319.2%)<0.001 512.4%(5.7\u201318.7%)<0.001 219.6%(3.0\u201333.4%)0.023 513.5%(5.0\u201321.3%)0.002 213.3%(4.1\u201321.6%)0.005Cardiorespiratory Hospitalization717.9%(15.0\u201320.8%)<0.001 617.7%(14.5\u201320.8%)<0.001 1 \u2013 \u2013 417.4%(13.5\u201321.1%)<0.001 318.6%(14.1\u201322.9%)<0.001All-cause Hospitalization118.4%(5.7\u201311.0%)<0.001 88.3%(4.5\u201312.0%)<0.001 38.9%(5.4\u201312.2%)<0.001 76.4%(4.1\u20138.6%)<0.001 412.6%(7.8\u201317.2%)<0.001Post-in\ufb02uenza Mortality2 22.2%(-18.2\u201348.8%)0.240 1 \u2013 \u2013 1 \u2013 \u2013 1 \u2013 \u2013 1 \u2013 \u2013Pneumonia/In\ufb02uenza Mortality339.9%(18.6\u201355.6%)<0.001 243.2%(18.1 \u2013 60.6%)0.002 1 \u2013 \u2013 1 \u2013 \u2013 243.2%(18.1 \u2013 60.6%)0.002Cardiorespiratory Mortality327.7%(13.2\u201332.0%)<0.001 227.3%(20.3 \u2013 33.6%)<0.001 1 \u2013 \u2013 1 \u2013 \u2013 227.3%(20.3 \u2013 33.6%)<0.001All-cause Mortality5 2.5%(-5.1\u20139.5%)0.514 4 4.6%(-12.6\u201319.3%)0.575 1 \u2013 \u2013 3 0.7%(-4.3\u20135.6%)0.768 217.3%(0.2\u201331.5%)0.048aDetermined using national CDC viral surveillance data of circulating strains in adults 65 years of age and older.bBased on CDC data on viral antigenic characterization comparing reference vaccine strains to circulating viruses; mismatched seasons includes seasons of antigenicmismatch (2009\u201310, 2014\u201315, 2018\u201319) as well as seasons where egg-adapted vaccine strains may have affected vaccine effectiveness (2012\u201313, 2016\u201317, 2017\u201318). cA random-effects model with DerSimonian-Laird estimators was used to calculate the pooled OR across multiple studies and in\ufb02uenza seasons.dProbable/laboratory con\ufb01rmed in\ufb02uenza-like illness.eICD-9-CM 487 coded hospitalizations.fICD-9-CM 480\u2013486 coded hospitalizations.gICD-9-CM 480\u2013488 coded hospitalizations.J.K.H. Lee et al.Vaccine xxx (xxxx) xxx\n10Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Immunogenit\u00e4tvon HD-QIV (IV4-HD) versus HD-TIV (IV3-HD)insgesamt>2500 ProbandenIV4-HD (2xA, 2xB) IV3-HD (IV3-HD1 + IV3-HD2)IV3-HD1 (2xA, Victoria) IV3-HD2 (2xA, Yamagata) \nChang et al., Vaccine, 2019\ntiters (data not shown). Thus, the primary immunogenicity objec-tive of non-inferiority for all four strains for both GMTs and sero-conversion rates was con\ufb01rmed.3.2.2. HAI antibody response to in\ufb02uenza A strainsPost-vaccination HAI GMTs were similar between IIV4-HD andthe pooled IIV3-HDs for strains A/H1N1 (312 [95%CI: 292\u2013332]for IIV4-HD vs. 374 [95%CI: 341\u2013411] for IIV3-HD) and A/H3N2(563 [95%CI: 525\u2013603] for IIV4-HD vs. 594 [95%CI: 540\u2013653] forIIV3-HD) (Table 4). Seroconversion rates for the A/H1N1 strainwere 50.4% (95%CI: 48.0%\u201352.8%) for IIV4-HD and 53.7% (95%CI:50.2%\u201357.1%) for the pooled IIV3-HDs. For the A/H3N2 strain, sero-conversion rates were 49.8% (95%CI: 47.3%\u201352.2%) for IIV4-HD and50.5% (95%CI: 47.1%\u201353.9%) for the pooled IIV3-HDs.3.2.3. HAI antibody response to the B Victoria-lineage strainFor the B Victoria-lineage strain, the post-vaccination HAI GMTwas similar for IIV4-HD (516 [95%CI: 488\u2013545]) and IIV3-HD con-taining the B Victoria-lineage strain (IIV3-HD1) (476 [95%CI: 426\u2013532]) but lower for IIV3-HD containing the B Yamagata-lineagestrain (IIV3-HD2) (253 [95%CI: 226\u2013283]) (Table 4). Seroconver-sion rates were 36.5% (95%CI: 34.2%\u201338.9%) for IIV4-HD, 39.0%(95%CI: 34.3%\u201343.8%) for IIV3-HD1, and 15.2% (95%CI: 11.9%\u201318.9%) for IIV3-HD2.Table 2Subject baseline characteristics.IIV4-HD IIV3-HD1 IIV3-HD2Characteristic N = 1680 N = 423 N = 430Sex, n (%)Male 703 (41.8) 172 (40.7) 191 (44.4)Female 977 (58.2) 251 (59.3) 239 (55.6)Age (years)Mean (SD) 72.9 (5.66) 72.8 (5.82) 73.2 (5.50)/C2175 years, n (%) 594 (35.4) 141 (33.3) 164 (38.1)Racial origin, n (%)American Indian or AlaskaNative9 (0.5) 2 (0.5) 3 (0.7)Asian 12 (0.7) 2 (0.5) 3 (0.7)Black or African American 114 (6.8) 36 (8.5) 32 (7.4)White 1532 (91.2) 380 (89.8) 385 (89.5)Multiple 6 (0.4) 1 (0.2) 2 (0.5)Not reported 4 (0.2) 1 (0.2) 4 (0.9)Ethnicity, n (%)Hispanic or Latino 47 (2.8) 9 (2.1) 13 (3.0)Not Hispanic or Latino 1630 (97.0) 413 (97.6) 415 (96.5)Unknown 0 (0.0) 0 (0.0) 1 (0.2)Body mass index categories, n (%)Underweight (<18.5 kg/m2) 17 (1.0) 0 (0.0) 1 (0.2)Normal weight (18.5\u201324.9 kg/m2) 355 (21.1) 91 (21.5) 82 (19.1)Overweight (25\u201329.9 kg/m2) 565 (33.6) 156 (36.9) 151 (35.1)Obese (/C2130) 691 (41.1) 164 (38.8) 183 (42.6)Missing 52 (3.1) 12 (2.8) 13 (3.0)Smoking habits, n (%)Never 1033 (58.1) 251 (56.7) 284 (63.1)Current 110 (6.2) 22 (5.0) 23 (5.1)Former 634 (35.7) 170 (38.4) 143 (31.8)History of chronic medicalconditions, n (%)992 (55.8) 256 (57.8) 222 (49.3)Ongoing chronic medicalconditions at inclusion, n (%)835 (47.0) 225 (50.8) 185 (41.1)Concomitant medications, n (%)Any 1345 (75.7) 332 (74.9) 333 (74.0)Category 1a1011 (56.9) 254 (57.3) 264 (58.7)Category 2b24 (1.4) 3 (0.7) 3 (0.7)Category 3c44 (2.5) 6 (1.4) 12 (2.7)Category 4d876 (49.3) 216 (48.8) 217 (48.2)In\ufb02uenza vaccination theprevious year, n (%)1339 (75.4) 308 (69.5) 333 (74.0)Values are for the full analysis set. Abbreviations: IIV3-HD1, high-dose trivalentinactivated in\ufb02uenza vaccine containing the Victoria-lineage B strain; IIV3-HD2,high-dose trivalent inactivated in\ufb02uenza vaccine containing the Yamagata-lineageB strain; IIV4-HD, high-dose quadrivalent inactivated in\ufb02uenza vaccine; SD, stan-dard deviation.aMedications affecting or that may affect safety evaluation (e.g. antipyretics,analgesics, non-steroidal anti-in\ufb02ammatory drugs).bMedications affecting or that may affect immune response (e.g. other vaccines,blood products, antibiotic classes that may interfere with bioassays, immune sup-pressors, immune modulators with immunosuppressive properties, and anti-pro-liferative drugs such as DNA synthesis inhibitors).cMedications affecting or that may affect both safety and immune response (e.g.,steroids/corticosteroids).dStatins.312 563 516 578 374 594 476 580 \n10100100010000\nA/H1N1 A/H3N2 B Victoria B YamagataHAI GMT (95% CI) IIV4-HDIIV3-HD\n50.4% 49.8% 36.5% 46.6% 53.7% 50.5% 39.0% 48.4% \n0%10%20%30%40%50%60%70%\nA/H1N1 A/H3N2 B Victoria B YamagataSeroconversion rate (95% CI) IIV4-HDIIV3-HDRatio of day 28 HAI GMT (IIV4-HD/IIV3-HD) 0.83 0.95 1.08 1.00 95% CI (0.744, 0.932) (0.842, 1.066) (0.958, 1.224) (0.881, 1.129) Non-inferior Yes Yes Yes Yes \nDifference in seroconversion rate (IIV4-HD-IIV3-HD) -3.27 -0.71 -2.41 -1.75 95% CI (\u22127.37, 0.86) (\u22124.83, 3.42) (\u22127.66, 2.70) (\u22127.04, 3.53) Non-inferior Yes Yes Yes Yes A \nB \nFig. 2.Non-inferiority of HAI GMTs (A) and seroconversion rates (B). Values are forthe per-protocol analysis set. (A) The non-inferiority of IIV4-HD to each IIV3-HDgroup in terms of post-vaccination (day 28\u201335) HAI GMTs was demonstrated, if foreach of the three common strains, the lower limit of the 2-sided 95% CI for thedifference of log10(GMTs) > log10(1/1.5). For the A/H1N1 and A/H3N2 strains, thecomparator was the pooled IIV3-HDs, and for the B strains, the comparator was theIIV3-HD containing the same B-lineage strain. (B) Seroconversion was de\ufb01ned as (i)HAI titer <10 (1/dilution) at day 0 and a post-vaccination HAI titer/C2140 or (ii) a HAItiter/C2110 at day 0 and a/C214-fold increase in titer at day 28. The non-inferiority ofIIV4-HD to each IIV3-HD group in terms of seroconversion rates was demonstrated,if for each of the three common strains, the lower limit of the 2-sided 95% CI for thedifference of seroconversion rates was >/C010%. For the A/H1N1 and A/H3N2 strains,the comparator was the pooled IIV3-HDs, and for the B strains, the comparator wasthe IIV3-HD containing the same B-lineage strain. Abbreviations: CI, con\ufb01denceinterval; GMT, geometric mean titer; HAI, hemagglutinin inhibition titer; IIV3-HD1,high-dose trivalent inactivated in\ufb02uenza vaccine containing the Victoria-lineage Bstrain; IIV3-HD2, high-dose trivalent inactivated in\ufb02uenza vaccine containing theYamagata-lineage B strain; IIV4-HD, high-dose quadrivalent inactivated in\ufb02uenzavaccine.L.-J. Chang et al. / Vaccine 37 (2019) 5825\u201358345829H\u00f6hereAntigen-Dosis: tetravalentBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021AdjuvansMF59\ndatafromAnsaldiet al., Vaccine, 2008\nInfluenza strainPan/99Wyo/03Cal/04Wisc/05Seroprotection rate (%)020406080100non-adj MF59 \u2022TrivalenterInfluenza-ImpfstoffmitAdjuvansMF59 (\u00d6l-in-Wasser-Emulsion mitSqualen) seitEnde der 1990er in Europa zugelassenf\u00fcrPersonen\u00fcber65\nAK gegenSt\u00e4mme, die nichtimImpfstoffenthaltensind!Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Coleman et al., Influenza Other RespiViruses, 2021Systematic review and meta-analysis: a-TIV vs. TIV or QIV (2006/2007 \u20132019/2020)AdjuvansMF598\u2003|\u2003\u2003\u2002COLEMAN Et AL.\nBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Coleman et al., Influenza Other RespiViruses, 2021High-Dose vs. Adjuvans8\u2003|\u2003\u2003\u2002COLEMAN Et AL.\nBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021van Aalst et al., Vaccine, 2020High-Dose vs. AdjuvansRetrospektiveKohorten-Studie: a-TIV vs. HD-TIV (2016/2017 \u20132017/2018)ca. 2 Mio Personen, USA\nread-out: Hospitalisierung(respiratorisch) w\u00e4hrendInfluenza-SaisonUnterschiedezwischena-TIV und HD-TIV KohortebereitsimSommer!\u00e0werimHerbst HD-TIV bekommenwird, war schonimSommer kr\u00e4nker\u2026.\u00e0wenndieserBias ber\u00fccksichtigtwird, 12% \u00dcberlegenheitvon HD-TIVBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021AktuelleImpfempfehlungen(2021)\nwww.sozialministerium.atF\u00fcr\u00e4ltereErwachsene:\u2022Hochdosis(ab 60)\u2022Adjuvantiert(ab 65)\u2022Standard\u00d6sterreichischesNationalesImpfgremium:F\u00fcrPersonenab dem vollendeten60. bzw. 65. Lebensjahrwirddie Impfungmiteinemder Impfstoffe, die speziellf\u00fcrdieseAltersgruppeentwickeltwurden, empfohlenDeutsche STIKO:Aufgrund einer geringf\u00fcgigen, aber signifikanten \u00dcberlegenheitder Impfeffektivit\u00e4tbei \u00e4lterenMenschen wird f\u00fcralle Personen \u226560 Jahre ein quadrivalenterHochdosis-Impfstoff mit aktueller von der WHO empfohlener Antigenkombination empfohlen \u00e0zumerstenMal 2021/2022alle quadrivalent verf\u00fcgbarBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021\nEntwicklung\t\u2013\tIn\ufb02uenza\tDurchimpfungsrate\t\n*Berechnungsmethode:\tBev\u00f6lkerungsdaten\tlt\tStaNsNk\tAustria\t/\tAnzahl\tdistribuierter\tDosen\t(\u00d6VIH)\t\n0,00%\t2,00%\t4,00%\t6,00%\t8,00%\t10,00%\t12,00%\t14,00%\t16,00%\t18,00%\tDurchimpfungsrate\tin\tder\tGesamtbev\u00f6lkerung\t\u00d6sterreich\t2004-2019\t\nhttps://oevih.at/wp-content/uploads/2019/05/impfverhalten-_influenza_in_oesterreich_2019.pdfDurchimpfungsrate\n2020/202121,3%Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Influenza in Zeitenvon Corona\u2026.\nwww.sozialministerium.at\nCorona-Ma\u00dfnahmenverhindernauchsehreffektivInfluenza\nM\u00f6glichkeiteinerschwerenSaison 2021/2022, weilimletztenWinter die Exposition gefehlthat\u2026M\u00e4rz2020Saison 2020/2021Birgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Influenza in Zeitenvon Corona\u2026.Influenza-Impfungw\u00e4hrendder Pandemie:\u00e0Influenza-Erkrankungenbelastendas Gesundheitssystem\u00e0Co-InfektionenodersequentielleInfektionenwahrscheinlichbesondersgef\u00e4hrlich\u00e0Reduktionder Kontaktbeschr\u00e4nkungenin diesemWinter\u201cDie gleichzeitigeVerabreichungvon COVID-19-Impfstoffen mitanderenLebend-oderTotimpfstoffen(inkl. Influenza-Impfstoffen) istm\u00f6glichund sinnvoll(unterschiedlicheImpfstelle)\u201dBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021Influenza in Zeitenvon Corona\u2026.StudienzurgleichzeitigenGabe von Influenza und COVID-19 Impfstoffenz.B.NCT04969276 3. Dosis Spikevax+ HD-QIV>65 Jahregleichzeitig oder nur eines von beidenread-out: Immunogenit\u00e4tEntwicklungvon kombiniertenInfluenza / COVID-19 Impfstoffenz.B.NCT04961541, Phase I/II, NovavaxquadrivalenterInfluenza-Nanopartikel-Impfstoff + SARS-CoV-2 Spike Nanopartikel + Matrix M50-70 JahreImmunogenit\u00e4t/ SicherheitEntwicklungvon Influenza mRNA-Impfstoffenz.B.NCT04956575, Phase I/II, ModernamRNAf\u00fcr H\u00e4magglutinin(quadrivalent)>18 JahreImmunogenit\u00e4t/ SicherheitBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021\u2022Influenza-Impfstoffesindbei\u00e4lterenErwachsenenwenigerimmunogen und wirksamalsbeij\u00fcngerenPersonen\u2022SpezielleImpfstoffef\u00fcrSenioren: Hochdosisund adjuvantierterstmals2021/2022 alle Impfstoffequadrivalent verf\u00fcgbar\u2022Vergleicheund Meta-AnalysenzurklinischenWirksamkeitsindnichttrivial\u2026\u00e0RelevanzrandomisierterStudien\u2022In \u00d6sterreichpr\u00e4ferentielleEmpfehlungbeiderspeziellerImpfstoffef\u00fcrSenioren, in Deutschland nurHochdosis\u2022Einflussder COVID-19 Pandemieauf Influenza-Erkrankungund -ImpfungZusammenfassungBirgit Weinberger \u00d6GIT-Influenza imSenium\u201319.10.2021\n\u2026 nochFragen?", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}